The Duke University deal was originally signed in September 1998:
"Duke University ("DUKE") and CISTRON Biotechnology, Inc. ("SPONSOR") agree to amend the terms of the Clinical Study and Research Agreement entered into by the parties effective September 1, 1998..." 10-Q on 02/14/2000
On June 30, 1998, Cistron and Pasteur Merieux Serums & Vaccins, S.A. (PMS&V), the world's largest vaccine company, entered into a letter of intent for an option and license agreement pertaining to the use of IL-1 as a vaccine adjuvant in the fields of preventive and therapeutic vaccines.
On October 30, 1998, PMS&V purchased 1,333,333 shares of Cistron common stock at approximately $.75 per share and received warrants to purchase 666,667 additional shares at $.25 per share, for an aggregate price of $1,000,000. |
